Cargando…
Model-based assessment of public health impact and cost-effectiveness of dengue vaccination following screening for prior exposure
The tetravalent dengue vaccine CYD-TDV (Dengvaxia) is the first licensed vaccine against dengue, but recent findings indicate an elevated risk of severe disease among vaccinees without prior dengue virus (DENV) exposure. The World Health Organization currently recommends CYD-TDV only for individuals...
Autores principales: | España, Guido, Yao, Yutong, Anderson, Kathryn B., Fitzpatrick, Meagan C., Smith, David L., Morrison, Amy C., Wilder-Smith, Annelies, Scott, Thomas W., Perkins, T. Alex |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6625736/ https://www.ncbi.nlm.nih.gov/pubmed/31260441 http://dx.doi.org/10.1371/journal.pntd.0007482 |
Ejemplares similares
-
Cost-effectiveness of dengue vaccination in Puerto Rico
por: España, Guido, et al.
Publicado: (2021) -
Biased efficacy estimates in phase-III dengue vaccine trials due to heterogeneous exposure and differential detectability of primary infections across trial arms
por: España, Guido, et al.
Publicado: (2019) -
Dengue infections in travellers
por: Wilder-Smith, Annelies
Publicado: (2012) -
Dengue vaccine development: status and future
por: Wilder-Smith, Annelies
Publicado: (2019) -
Household costs of hospitalized dengue illness in semi-rural Thailand
por: Tozan, Yesim, et al.
Publicado: (2017)